Patients With Metastatic Colorectal Cancer Having Less Surgery, Yet Survival Rates Improving

With the dawn of the modern era of new chemotherapeutic and biologic agents available for managing their disease, patients with metastatic colorectal cancer are undergoing less surgery for the removal of their primary tumors.

With the dawn of the modern era of new chemotherapeutic and biologic agents available for managing their disease, patients with metastatic colorectal cancer are undergoing less surgery for the removal of their primary tumors, according to research from The University of Texas MD Anderson Cancer Center.

The study, published in JAMA Surgery, also found an increase in overall survival in this patient population. Yet the researchers are left with questions about whether the rates of primary tumor resection (PTR) have not kept up with chemotherapy benefits and whether PTR rates should be even lower.

Read the full press release from MD Anderson: http://bit.ly/1u8Nqey